期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替比夫定联合阿德福韦酯治疗拉米夫定耐药的慢性乙型肝炎患者疗效观察 被引量：6

在线阅读 下载PDF
导出
摘要 目的探讨拉米夫定耐药患者的治疗方法。方法选取拉米夫定治疗失效的慢性乙型肝炎患者60例,28例接受阿德福韦酯治疗,32例接受替比夫定联合阿德福韦酯治疗,观察52周。结果在治疗52周时,联合治疗组HBV DNA转阴率为98%,阿德福韦治疗组为90%(P>0.05),无统计学差异;联合治疗组HBeAg转阴率为37.5%,阿德福韦治疗组为7.0%,联合治疗组HBeAg血清学转换率为18.8%,阿德福韦治疗组为3.5%较(P<0.01),具有统计学差异;联合治疗组ALT复常率为93%,阿德福韦治疗组为75%(P<0.01),存在统计学差异。结论替比夫定联合阿德福韦酯联合治疗拉米夫定治疗失效的慢性乙型肝炎患者具有显著的临床疗效,无明显的不良反应。
作者 常家宝 薛蓉 冯艳红 戴玮玮 李丽 吴卫锋 邱洁 杨永峰
机构地区 东南大学附属南京市第二医院肝病科
出处 《实用肝脏病杂志》 CAS 2012年第3期257-258,共2页 Journal of Practical Hepatology
关键词 慢性乙型肝炎 拉米夫定 替比夫定 阿德福韦酯
分类号 R512.62 [医药卫生—内科学]
  • 相关文献

参考文献8

  • 1慢性乙型肝炎防治指南(2010年版)[J].实用肝脏病杂志,2011,14(2):81-89. 被引量：436
  • 2Fungs K,Lok AS. Management of hepatitis B patient with antiviral resistance. Antivir Ther,2004,9:1013-1026.
  • 3Liaw YF ,Gane E,Leung N,et al. 2-Year GLOBE trial results:tell~ivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology,2009,136:486-495.
  • 4Lai CL. Leung N,Teo EK,et al. A 1-year trial of telbivudine, lamivudine,and the combination in patients with hepatitis B e antigen -positive chronic hepatitis B. Gastroenterology, 2005,129:528-536.
  • 5Marcellin P,Chan HLY,Lai CL,et al. In hepatitis B patient treated with either adefovir or telbivudine,maximal early HBV suppression at 24 weeks predicts optimal one-year efficacy. J Hepatol, 2007,46( suppl 1):s193.
  • 6中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量：14021
  • 7侯金林 于乐成.慢性乙型肝炎抗病毒治疗方案优化[J].中华肝脏病杂志,2009,.
  • 8贾继东,侯金林,尹有宽,徐道振,谭德明,牛俊奇,周霞秋,王宇明,朱理珉,贺永文,任红,万谟彬,陈成伟,巫善明,陈亚岗,许家璋,王勤环,魏来,马红.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志,2007,15(5):342-345. 被引量：141

二级参考文献9

  • 1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
  • 2Lok AS, McMahon B J; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology, 2004, 39: 857-861.
  • 3Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
  • 4Mangi A, Villani MR, Minerva N, et al. Efficacy of 5MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: a randomized controlled trial. J Hepatol, 2001,34: 441-446.
  • 5Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology, 2003,37: 600-609.
  • 6Strader DB, Waright T, Thomas DL, et al. Diagnosis, management,and treatment of hepatitis C. Hepatology, 2004, 39: 1147-1171.
  • 7Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis Bviremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis, 1999, 180: 1757-1762.
  • 8Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology, 2001, 34: 785-791.
  • 9Jang JW, Bae SH, Chio JY, et al. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg response. J Gastroenterol Hepatol, 2006, 21: 384-391.

共引文献14528

同被引文献61

  • 1王宇明,汤勃.2012亚太肝脏研究学会新版慢性乙型肝炎指南特点的探讨[J].中国医学前沿杂志（电子版）,2012,4(9):72-74. 被引量：2
  • 2Levine S,Hernandez D,Yamanaka G,et al. Efficacies ofentecavir against lamivudine resistant hepatitis B virus repli-cation and recombinant polymerases in vitro [J]. AntimicrobAgents Chemother,2002,46 (8) : 2525-2532.
  • 3Park JW, Kim HS, Seo DD, et al. Long-term efficacy ofentecavir in adefovir-refractory chronic hepatitis B patientswith prior lamivudine resistance [J]. J Viral Hepatitis,2011, 18 (10); 475-481.
  • 4Yim HJ, Seo YS,Yoon EL, et al. Adding adefovir vs switc-hing to entecavir for lamivudine-resistant chronic hepatitis B(ACE study) : a 2-year follow-up randomized controlled trial[J]. Liver Int, 2013, 33 (2): 244-254.
  • 5Kwak MS* Choi JW, Lee JS, et al. Long-term efficacy ofentecavir therapy in chronic hepatitis B patients with antivi-ral resistance to lamivudine and adefovir [J]. J Viral Hepati-tis, 2011, 18 (10): 432-438.
  • 6Lee GH, Aung MO,Dan YY, et al. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavirresistance [J]. J Med Virol, 2013, 85 (1): 26-33.
  • 7Kim JH, Kim YS, Jung YK,et al. The short-term effica-cy of entecavir in lamivudine-resistant chronic hepatitis B:influence of sequential adefovir-refractoriness [J]. Hepato-gastroenterology, 2012,60 (125). [Epub ahead of print].
  • 8Benhamou Y, Bochet M, Thibault V, et al. Safety and ef-ficacy of adefovir dipivoxil in patients co-infected with HIV-1and lamivudine-resistant hepatitis B virus : an open label pi-lot study [J]. Lancet, 2001,358 (9283) : 718-723.
  • 9Chen CH, Wang JH, Lu SN, et al. Characteristics of ade-fovir resistance in patients with or without lamivudine-re-sistant hepatitis B virus treated with adefovir: a 4-year ex-perience [J]. LiverInt, 2011,31 (2): 206-214.
  • 10Kim MC. The level of HBV DNA at month 12 is an impor-tant predictor of virological breakthrough during adefovirmonotherapy in chronic hepatitis B patients with lamivudineresistance [J]. Digest Dis Sci,2011,56 (4) ; 1215-1221.

二级引证文献17

实用肝脏病杂志
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部